BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 26.49 USD 1.07% Market Closed
Market Cap: 5B USD
Have any thoughts about
BridgeBio Pharma Inc?
Write Note

Wall Street
Price Targets

BBIO Price Targets Summary
BridgeBio Pharma Inc

Wall Street analysts forecast BBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BBIO is 50.52 USD with a low forecast of 37.37 USD and a high forecast of 73.5 USD.

Lowest
Price Target
37.37 USD
41% Upside
Average
Price Target
50.52 USD
91% Upside
Highest
Price Target
73.5 USD
177% Upside

BBIO Last Price Targets
BridgeBio Pharma Inc

The latest public price target was made on Oct 24, 2024 by David Lebowitz from Citigroup , who expects BBIO stock to rise by 70% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
David Lebowitz
Citigroup
45 USD
Upside 70%
1 month ago
Oct 24, 2024
Citi Reiterates Buy Rating on BridgeBio Pharma (BBIO)
StreetInsider
Mani Foroohar
Leerink Partners
46 USD
Upside 74%
2 months ago
Oct 17, 2024
BridgeBio price target lowered to $46 from $47 at Leerink
TheFly
Biren Amin
Piper Sandler
46 USD
Upside 74%
3 months ago
Sep 11, 2024
Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
StreetInsider
Salim Syed
Mizuho Securities
53 USD
Upside 100%
3 months ago
Sep 3, 2024
Mizuho Reiterates Outperform Rating on BridgeBio Pharma (BBIO)
StreetInsider
Danielle Brill
Raymond James
46 USD
Upside 74%
5 months ago
Jun 24, 2024
Raymond James on BridgeBio Pharma (BBIO): 'We expect the topline nominal win for HELIOS-B will send BBIO shares downward'
StreetInsider
Kostas Biliouris
BMO Capital
37 USD
Upside 40%
6 months ago
Jun 5, 2024
BMO Capital Reiterates Outperform Rating on BridgeBio Pharma (BBIO)
StreetInsider
Tiago Fauth
Wells Fargo
58 USD
Upside 119%
6 months ago
Jun 5, 2024
Wells Fargo Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
StreetInsider
Paul Choi
Goldman Sachs
50 USD
Upside 89%
6 months ago
May 30, 2024
Goldman Sachs Reiterates Buy Rating on BridgeBio Pharma (BBIO)
StreetInsider
Eliana Merle
UBS
47 USD
Upside 77%
6 months ago
May 28, 2024
BridgeBio Pharma (BBIO) PT Lowered to $47 at UBS
StreetInsider
Raghuram Selvaraju
H.C. Wainwright
43 USD
Upside 62%
7 months ago
May 20, 2024
BridgeBio Pharma (BBIO) PT Lowered to $43 at H.C. Wainwright
StreetInsider
Cory Kasimov
Evercore ISI
50 USD
Upside 89%
7 months ago
May 13, 2024
Evercore ISI Starts BridgeBio Pharma (BBIO) at Outperform
StreetInsider
Show More Price Targets
Show Less Price Targets
David Lebowitz
Citigroup
Price Target 45 USD
Upside/Downside 70%
View Source
Mani Foroohar
Leerink Partners
Price Target 46 USD
Upside/Downside 74%
View Source
Biren Amin
Piper Sandler
Price Target 46 USD
Upside/Downside 74%
View Source
Salim Syed
Mizuho Securities
Price Target 53 USD
Upside/Downside 100%
View Source
Danielle Brill
Raymond James
Price Target 46 USD
Upside/Downside 74%
View Source
Kostas Biliouris
BMO Capital
Price Target 37 USD
Upside/Downside 40%
View Source
Tiago Fauth
Wells Fargo
Price Target 58 USD
Upside/Downside 119%
View Source
Paul Choi
Goldman Sachs
Price Target 50 USD
Upside/Downside 89%
View Source
Eliana Merle
UBS
Price Target 47 USD
Upside/Downside 77%
View Source
Raghuram Selvaraju
H.C. Wainwright
Price Target 43 USD
Upside/Downside 62%
View Source
Cory Kasimov
Evercore ISI
Price Target 50 USD
Upside/Downside 89%
View Source
Show More Price Targets
Show Less Price Targets
BridgeBio Pharma Inc Competitors:
Price Targets
002675
Yantai Dongcheng Biochemicals Co Ltd
34% Upside
STTK
Shattuck Labs Inc
6% Upside
OCGN
Ocugen Inc
625% Upside
1952
Everest Medicines Ltd
31% Downside
1801
Innovent Biologics Inc
65% Upside
RYTM
Rhythm Pharmaceuticals Inc
32% Upside
MCRB
Seres Therapeutics Inc
332% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
78% Upside

Revenue
Forecast

Revenue Estimate
BridgeBio Pharma Inc

The compound annual growth rate of BridgeBio Pharma Inc's revenue for the next 4 years is 212%.

N/A
Past Growth
212%
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Operating Income
Forecast

Operating Income Estimate
BridgeBio Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
BridgeBio Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-22%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BBIO's stock price target?
Price Target
50.52 USD

According to Wall Street analysts, the average 1-year price target for BBIO is 50.52 USD with a low forecast of 37.37 USD and a high forecast of 73.5 USD.

What is BridgeBio Pharma Inc's Revenue forecast?
Projected CAGR
212%

The compound annual growth rate of BridgeBio Pharma Inc's revenue for the next 4 years is 212%.

Back to Top